Industry News

QMED - FDA Upbeat about Medical Device Approval Times
Ireland : CELEBREX generic version introduced by Actavis
Abbott Completes Acquisition of Veropharm
EU REGULATORS SUSPECT FOUL PLAY BY GVK BIO OVER CLINICAL TRIALS
Teva Canada Announces the Launch of (Pr)Teva-Erlotinib, a generic of (Pr)Tarceva�
Lakewood-Amedex Submits Investigational New Drug Application for Bisphosphocin� Nu-3 for the Treatment of Diabetic Foot Infections
Good Documentation Practices Are Key for Government Drug Reimbursement Establishing Procedures and Recording Assumptions Help Companies Address Regulatory-Based Inquiries
Aprecia Pharmaceuticals Receives FDA Acceptance for Filing for First Product Using Advanced ZipDose� Technology
Endo Completes Acquisition of Rights to Natesto� Testosterone Nasal Gel
FDA Approves Combo Device for Managing Diabetes
Sanofi Receives FDA Approval of Priftin� (rifapentine) Tablets for the Treatment of Latent Tuberculosis Infection
Migraine Prevention Device CEFALY� Opens U.S. Office for Faster Delivery, Quicker Relief U.S. migraine patients with a prescription may now buy device from US Cefaly headquarters in Connecticut
Merial acquires Merck manufacturing facility in Barceloneta, Puerto Rico; Acquisition expands Merial's global manufacturing footprint
Battelle - DeviceSecure Services Help Medical Device Developers Stay a Step Ahead of Hackers
Migraine Prevention Device CEFALY� Opens U.S. Office for Faster Delivery, Quicker Relief U.S. migraine patients with a prescription may now buy device from US Cefaly headquarters in Connecticut
FDA Approves Amgen's XGEVA� (Denosumab) For The Treatment Of Hypercalcemia Of Malignancy Refractory To Bisphosphonate Therapy This Approval Provides a New Treatment Option for a Patient Population With High Unmet Medical Need
New Drug Labels to Aid Pregnant, Nursing Women
PetVivo's Merger Partner Gel-Del Receives Grant Notices for Two EU Patents
Sanofi Receives FDA Approval of Priftin� (rifapentine) Tablets for the Treatment of Latent Tuberculosis Infection
US FDA approves the labeling update of Abilify Maintena (aripiprazole) for extended-release injectable suspension to describe new clinical data for the treatment of acutely relapsed adults with schizophrenia
Merck to Acquire Cubist Pharmaceuticals for $102 Per Share in Cash
Revive Therapeutics Ltd. Announces US FDA Acceptance of IND to Commence Clinical Trial for Bucillamine for the Treatment of Gout
FDA Approves PulmoFlow's Tobramycin & Nebulizer Combination for Cystic Fibrosis
US FDA approves Mylan's NDA's for two dosages of abacavir/lamivudine tablets
Eisai opens new packaging facility at Hatfield production plant in U.K.